Sicor, one of two legal entities of the Italian business unit of TAPI, operates two production sites in Northern Italy, with the Santhià site situated midway on the highway between Milan and Torino.
Sicor’s plants provide a global platform for the manufacture and marketing of APIs for injectable, inhalation, topical and nasal products. These s...
Sicor, one of two legal entities of the Italian business unit of TAPI, operates two production sites in Northern Italy, with the Santhià site situated midway on the highway between Milan and Torino.
Sicor’s plants provide a global platform for the manufacture and marketing of APIs for injectable, inhalation, topical and nasal products. These specialized plants possess a high level of expertise in the production of steroids, hormones and cytotoxic products. Sicor produces about 60 active ingredients and offers one of the widest ranges of anti-cancer drugs on the market today. The product line also includes anti-inflammatories and muscle relaxants.
The Santhià site has accumulated extensive experience and proven expertise in the production and handling of high-potent compounds (OHC 4, 5 and 6), as well as in contract manufacturing projects. The site maintains dedicated facilities for the production of hormonal compounds, enabling a future growth path within this medication class. The site is regularly audited by leading regulatory agencies (including the FDA, EMA/MHRA and HALMED) and TAPI’s business partners. Sicor Soc Italiana Corticosteroidi Srl engages in production of active pharmaceutical ingredients (API). The company is based in Milan, Italy. Sicor Soc Italiana Corticosteroidi Srl operates as a subsidiary of Teva Pharmaceutical Industries Ltd.
Market Place
